Continued Level of Significant Insider Selling at Exelixis (EXEL)

Wednesday, September 20, 2017 10:15 PM ET

Continued Level of Significant Insider Selling at Exelixis (EXEL)

A notable insider sale of the shares of Exelixis was indicated in a form 4 document filed with the SEC today, showing — Dr Stelios Papadopoulos, Director — disposed of 200,000 shares in the company having a market value of approximately $5,535,387. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the disposition of 160,640 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 360,640 shares and have averaged 120,213 shares per transaction over this time period.

During the last 90 days, the number of insider buy/sell trades at Exelixis is greater than the 266-company peer group average. Bio Therapeutic Drugs peer group saw 302 buy/sell trades during this period for an average of 1.1 transactions per company. The number of shares per buy/sell trade for Exelixis insiders was also higher. Within the peer group there were 8,414,595 shares purchased and 15,318,884 shares sold with company insiders disposing of 22,862 shares on average.

The data obtained in composing and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.